Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene

Circulation

Volumn 96, Issue 10, 1997, Pages 3570-3578

  Madeddu, Paolo ^a,b   Varoni, Maria Vittoria ^c   Palomba, Domenico ^c   Emanueli, Costanza ^c   Demontis, Maria Piera ^c   Glorioso, Nicola ^c   Dessì Fulgheri, Paolo ^c   Sarzani, Riccardo ^c   Anania, Vittorio ^c  

^a NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c NONE

Author keywords

Bradykinin; Genes; Kinins; Receptors

Indexed keywords

BRADYKININ;

ANIMAL CELL; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; ENZYME INHIBITION; GENE DISRUPTION; KALLIKREIN KININ SYSTEM; MOUSE; NATRIURESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0030729669     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.10.3570     Document Type: Article

References (32)

1. Vanhoutte PM. Endothelium and control of vascular function: state of the art lecture. Hypertension. 1989;13:658-667.
2. Willis LR, Ludens JH, Hook JB, Williamson HE. Mechanisms of natriuretic action of bradykinin. Am J Physiol. 1969;217:F1-F15.
3. Granger JP, Hall JE. Acute and chronic actions of bradykinin on renal function and arterial pressure. Am J Physiol. 1985;248: F87-F92.
4. Carretero OA, Scicli AG. Local hormonal factors (intracrine, autocrine and paracrine) in hypertension. Hypertension. 1991; 18(suppl I):I58-I69.
5. 2-receptor antagonists. Hypertension. 1991;17:107-115.
6. 2-receptors alters the adult cardiovascular phenotype in rats. Hypertension. 1995;25:453-459.
7. 2-receptors enhances the slow vasopressor response to angiotensin II. Hypertension. 1993;23:646-652.
8. Madeddu P, Anania V, Pinna Parpaglia P, Demontis MP, Varoni MV Fattaccio MC, Glorioso N. Chronic kinin receptor blockade induces hypertension in deoxycorticosterone-treated rats. Br J Pharmacol. 1993;108:651-657.
9. Berry TD Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, Kuida H, Williams RR. A gene for high kallikrein may protect against hypertension in Utah kindreds. Hypertension. 1989;13:3-8.
10. Keiser HR, Geller RG, Margolius HS, Pisano JJ. Urinary kallikrein in hypertensive animal models. Fed Proc. 1976;35:199-202.
11. Bianchi G, Barber BR, Torielli L, Ferrari P. The Milan hypertensive strain. In: Swales JD, ed. Textbook of Hypertension. Oxford, UK: Blackwell Scientific Publications; 1994:457-461.
12. Carretero OA, Amin VM, Ocholik T, Scicli AG, Koch J. Urinary kallikrein in rats bred for their susceptibility and resistance to the hypertensive effect of salt: a new radioimmunoassay for its direct determination. Circ Res. 1978;42:727-731.
13. Pravanec M, Kren V, Kunes J, Scicli AG, Carretero OA, Simonet L, Kurtz TW. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension. 1991;17:242-246.
14. 2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem. 1995;23:13706-13710.
15. Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci. 1996;19: 177-181.
16. Shimamoto K, Ando T, Nakao T, Sakuma M, Miyahara M. A sensitive radioimmunoassay method for urinary kinins in man. J Lab Clin Med. 1978;91:721-728.
17. 1-receptor-related peptides: antagonists. Hypertension. 1996;28:833-839.
18. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension. 1993;21:660-666.
19. Sarzani R, Fallo P, Dessì-Fulgheri P, Pistorello M, Lanari A, Paci VM, Mantero F, Rappelli A. Local renin-angiotensin system in human adrenals and aldosteronomas. Hypertension. 1992;19: 702-707.
20. Madeddu P, Varoni MV, Demontis MP, Pinna-Parpaglia P, Glorioso N, Anania V. Urinary kallikrein: a marker of blood pressure sensitivity to salt. Kidney Int. 1996;49:1422-1427.
21. 2 receptor. Hypertension. 1997;29: 488-493.
22. Parratt JR. Protection of the heart by ischemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol Sci 1994;15:19-25.
23. Linz W, Wieimer G, Gholke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
24. Imamura M, Levi R. Bradykinin promotes exocytotic and carrier-mediated norepinephrine release in myocardial ischemia-reperfusion. Circulation. 1995;92(suppl I):I568. Abstract.
25. Schorning A. Catecholamines in myocardial ischemia: systemic and cardiac release. Circulation. 1990;82:13-22.
26. 2 receptor knockout mice. Biochem Biophys Res Commun. 1996;224:625-630.
27. Barajas L, Powers K, Carretero O, Scicli AG, Inagami T. Immunocytochemical localization of renin and kallikrein in the rat renal cortex. Kidney Int. 1986;29:965-970.
28. Majima M, Mizogami S, Kuribayashi Y, Katori M, Oh-ishi S. Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension. 1994;24:111-119.
29. Majima M, Yoshida O, Mihara H, Muto T, Mizogami S, Kuribayashi Y, Katon M, Oh-ishi S. High sensitivity to salt in kininogen-deficient Brown Norway Katholiek rats. Hypertension. 1993;22:705-714.
30. Ferri C, Bellini C, Carlomagno A, Perrone A, Santucci A. Urinary kallikrein and salt sensitivity in essential hypertensive males. Kidney Int. 1994;46:780-788.
31. 2 and cGMP: effects of altered sodium intake. Hypertension. 1994;16:436-440.
32. Madeddu P, Glorioso N, Varoni MV, Demontis MP, Fattaccio C, Anania V. Cardiovascular effects of brain kinin receptor blockade in spontaneously hypertensive rats. Hypertension. 1994;231:189-192.